Term
|
Definition
| treatment for cytopenia (myelodysplasia, aplastic anemia) |
|
|
Term
|
Definition
| demethylate DNA, turn on genes, 25-30% response (myelodysplasia) |
|
|
Term
|
Definition
| treatment for 5Q(-), >50% become non-transfusion dependent (myelodysplasia) |
|
|
Term
| antithymocyte globulin/cyclosporine |
|
Definition
| suppress Tcells, helps autoimmune causes (aplastic anemia) |
|
|
Term
|
Definition
| blocks C5 activation, stops hemolysis (PNH) |
|
|
Term
|
Definition
| slows down marrow (CML, Polycythemia Vera,***Essential Thrombocytosis most effective) |
|
|
Term
| imatinib/dasatinib/nilotinib |
|
Definition
| bind BCR-abl, 95% karyotypic remission (CML) |
|
|
Term
|
Definition
| slows down marrow (CML 5% karyotipic remission, Polycythemia Vera, Hairy Cell Leukemia improves blood counts) |
|
|
Term
|
Definition
| prevents clotting (Essential Thrombocytosis) |
|
|
Term
|
Definition
| lowers platelets (Essential Thrombocytosis), acetylates COX-1, decreases prostaglandin (ECs) and thromboxane (Platelets 10dys) synthesis |
|
|
Term
|
Definition
| currently in clinical trials (PCV, ET, Myelofibrosis) |
|
|
Term
|
Definition
| treatment for AML, possible tumor lysis syndrome/renal failure |
|
|
Term
|
Definition
| for APML, causes clinical remission, does not clear malignant clone, chemo added for 80% cure rate, possible Retinoic Acid Syndrome |
|
|
Term
| Vincristine/prednisone/daunarubicin/L-asparaginase |
|
Definition
|
|
Term
|
Definition
| more aggressive therapy for ALL |
|
|
Term
|
Definition
| intrathecal chemo for ALL |
|
|
Term
| 6-mercaptopurine/methotrexate |
|
Definition
| 2yrs oral maintenance therapy for ALL |
|
|
Term
|
Definition
| 50% response, determine if patient will tolerate and avoid use in induction regimen, high dose with autologous BMT (Multiple Myeloma, Amyloidosis) |
|
|
Term
| Vincristine/adriamycin/prednisone (VAD) |
|
Definition
| IV, better survival (multiple myeloma) |
|
|
Term
| Thalidomide/revlimid/dexamethasone |
|
Definition
| hurts plasma cells, use before high dose melphalan (Multiple Myeloma) |
|
|
Term
|
Definition
|
|
Term
|
Definition
| for anemia, enhances cancer growth (multiple myeloma) |
|
|
Term
|
Definition
| treatment for Waldenstrom's Macroglobulinemia/CLL |
|
|
Term
|
Definition
| anti-CD20 antibody, works on immature plasmacytes, added to chlorambucil/fludarabine (Waldenstrom's Macroglobulinemia, CLL) |
|
|
Term
| Thalidomide/velcade/revlimide |
|
Definition
| chemo before autologous stem cell transplant (Waldenstrom's Macroglobulinemia) |
|
|
Term
|
Definition
| treatment for Hodgkin's Disease |
|
|
Term
|
Definition
| alkylates DNA, slows blood response, 50% response (CLL) |
|
|
Term
|
Definition
| more myelossupressive, 70% response (CLL) |
|
|
Term
|
Definition
| alkylates, better long-term prognosis and less immunosuppression (CLL) |
|
|
Term
|
Definition
| inhibits DNA synthesis, infused with pump, no emesis/alopecia, 80% remission, 64% 10yr remission (Hairy Cell Leukemia) |
|
|
Term
|
Definition
| tyrosine kinase inhibitor (mast cell infiltrates) |
|
|
Term
| Clindamycin/quinine, atovaquone/azithromycin, NOT chloroquinone |
|
Definition
|
|
Term
|
Definition
| for schistosomiasis larvae/adults |
|
|
Term
|
Definition
|
|
Term
|
Definition
| therapy for borreliosis, rickettia, ehrlichosis |
|
|
Term
|
Definition
| for late chronic borreliosis |
|
|
Term
| Tetracycline/chloramphenicol |
|
Definition
| bacteriostatic (ricketts) |
|
|
Term
|
Definition
| alternate therapy if pregnant (ehrlichosis) |
|
|
Term
|
Definition
|
|
Term
|
Definition
| alternate therapy for bartonellosis |
|
|
Term
|
Definition
| targets platelet ADP receptors, w/ aspirin for prevention of MI/stroke, 2-stage oxidation to active metabolites |
|
|
Term
|
Definition
|
|
Term
|
Definition
|
|
Term
|
Definition
| for vWD (only if not Type 3) |
|
|
Term
|
Definition
| preferred therapy for tularemia |
|
|
Term
| Doxycycline/chloramphenicol/ciprofloxacin |
|
Definition
| less effective for tularemia, fewer side effects |
|
|
Term
| streptomycin/tetracycline |
|
Definition
| most effective for yersinia pestis |
|
|
Term
| gentamicin/doxycycline/ciprofloxacin |
|
Definition
| added to therapy in Yersinia pestis |
|
|
Term
|
Definition
| 6wks-3mo treatment for brucellosis |
|
|
Term
| tetracycline/erythromicin/sulfonamides |
|
Definition
| treatment for lymphogranuloma venereum (chlamydia) |
|
|
Term
|
Definition
| treatment for infected mothers (toxoplasmosis), reduces transmission 50% |
|
|
Term
| spiramycin/pyrimethamine/sulfadiazine |
|
Definition
| for mothers of infected fetuses (toxoplasmosis) |
|
|
Term
| primethamine/leucovorin/sulfadiazine |
|
Definition
| for symptomatic infants (toxoplasmosis), shorter course if asymptomatic |
|
|
Term
|
Definition
| induces vWF release in subendothelium (Hemophilia A, vWD) |
|
|
Term
| cryoprecipitates (Factor VIII/vWF) |
|
Definition
|
|
Term
|
Definition
| surrogates for Factor VII, works with Factor IXa to activate Factor X |
|
|
Term
|
Definition
|
|
Term
|
Definition
| monocolonal Ab against gpIIbIIIa, prevents binding to fibrinogen/vWF, causes bleeding/cytopenia |
|
|
Term
| thiazide, sulfa, phenothiazines, dilantin |
|
Definition
|
|
Term
|
Definition
|
|
Term
| hirudin/danaparoid/argatroban |
|
Definition
| alternative anticoagulants (HIT) |
|
|
Term
|
Definition
| alternating glucoronic acid/glucosamine, sulfated sugars bind antithrombin III, 750-1000 kDa proteoglycan, cleaved to 5-30kDa fragments (~40 units), stored in mast cells, stimulates ATIII to irreversibly complex with thrombin/proteases, unfractioned form binds thrombin and ATIII together, for venous thrombosis/pulmonary embolisms, initiated with oral anticoagulants, better for recurring thromboembolisms, for coronary intervention/pulmonary bypass/catheters, IV immediate, SC 1-2h onset, dose-dependent half life |
|
|
Term
|
Definition
| more predictable pharmacokinetics (less monitoring), decreased incidence of thrombocytopenia/osteopenia/bleeding, dose-independent half-life, 1-5kDa |
|
|
Term
|
Definition
| activates ATIII only, core pentasaccharide of heparin, selectively inhibits Factor Xa, cannot reverse with protamine sulfate |
|
|
Term
|
Definition
| neutralizes negative charge on heparin, interacts with platelets/fibrinogen, 1mg/100U heparin, give slow IV to avoid anaphylaxis |
|
|
Term
|
Definition
| peptide, binds thrombin active site and extended recognition site, 1:1 complex blocks thrombin activity, for patients with HIT |
|
|
Term
|
Definition
| binds catalytic site of thrombin, for patients with HIT |
|
|
Term
| Phenylbutazone/sulfinpyrazone/metronidazole/allopurinol/cimetidine |
|
Definition
| plasma-protein bound drugs, displace warfarin |
|
|
Term
|
Definition
| inhibits reduction of vitamin K, reduced gamma-carboxylation of Factors II,VII,IX,X, reduces liver production of clotting proteins 30-50%, absorbed in GI, peakse 2-8h, half-life 40h, inactived by liver, plasma protein-bound, increased by drugs/vitamin k decrease, decreased by hypoprotenemia/CYP450 induction/Vitamin K increase |
|
|
Term
|
Definition
| longer half-life and duration |
|
|
Term
|
Definition
| shorter half-life and duration |
|
|
Term
|
Definition
| antagonize P2Y21 Receptor (ADP), block fibrinogen receptor, inhibit platelet aggregation |
|
|
Term
| Aspirin/ticlopidine/clopidogrel/abciximab |
|
Definition
| antiplatelet drugs, metabolized by P450, last 7-10 days post-treatment (platelets cleared), for prophylaxis of vascular occlusion/prevention of cerebrovascular events after stroke/treatment of MI/angioplasty and stents |
|
|
Term
|
Definition
| cyclic peptide inhibitor of RGD site of gpIIb/IIIa, does not bind vitronectin receptor, less effective than abciximab |
|
|
Term
|
Definition
| nonpetide inhibitor of gpIIbIIIa, no activity against vitronectin receptor |
|
|
Term
|
Definition
| for Hct <10/30 or Hgb <7-8, whole blood 450-500ml/35 days, packed cells 20-250ml/42 days, leukoreduced/irradiated/CMV tested, crossmatch and ID checks, NO ADDITIVES ON LINE, infuse over 1-4h, monitor for 15min and document results |
|
|
Term
|
Definition
| for <20,000/quantitative/qualitative problems, pooled from 6-10 donors or apheresis of a single donor, 5dy shelf life, HLA matched |
|
|
Term
| Fresh Frozen Plasma (FFP) |
|
Definition
| for clotting factor deficiency/ATIII deficiency/coumadin reversal, TTP/HUS plasma exchanges, separeated from whole blood and froezin within 8h, contains normal levels of clotting factors, check ABO compatibility, good for 1yr at -18C or 24h after thawing, monitor PT/PTT/fibrinogen |
|
|
Term
|
Definition
| thawed FFP to 1-6C, contains Factors VII,VIII/vWF/fibronectin/fibrinogen, check ABO compatibility, 4-6h shelf life after thawing, for decreased fibrinogen/vW disease/Hemophilia A/trauma |
|
|
